Kamada Ltd. (KMDA.TA) Initiates Phase 2/3 Clinical Trial Of Glassia To Treat Newly Diagnosed Pediatric Patients With Type 1 Diabetes
3/5/2014 9:18:29 AM
NESS ZIONA, Israel--(BUSINESS WIRE)--Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces the initiation of a Phase 2/3 clinical trial of Glassia®, the Company’s proprietary human Alpha-1 Antitrypsin (AAT), to treat newly diagnosed pediatric patients with type 1 diabetes (T1D). In T1D, autoimmune attacks occur on pancreatic beta cells that secrete insulin, thereby compromising insulin level and glycemic control. Over time there is progressive deterioration of self-insulin secretion, poor capability to control glucose levels, and eventually, full external insulin dependence.
Help employers find you! Check out all the jobs and post your resume.
comments powered by